ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
9.28
+0.25 (2.77%)
At close: May 6, 2026, 4:00 PM EDT
9.30
+0.02 (0.22%)
After-hours: May 6, 2026, 7:15 PM EDT
ARS Pharmaceuticals Employees
As of December 31, 2025, ARS Pharmaceuticals had 163 total employees, including 158 full-time and 5 part-time employees. The number of employees increased by 3 or 1.88% compared to the previous year.
Employees
163
Change
3
Growth
1.88%
Revenue / Employee
$517,043
Profits / Employee
-$1,050,908
Market Cap
921.48M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 163 | 3 | 1.88% | 158 | 5 |
| Sep 30, 2025 | 167 | 16 | 10.60% | 162 | 5 |
| Jun 30, 2025 | 167 | 139 | 496.43% | 162 | 5 |
| Dec 31, 2024 | 160 | 134 | 515.38% | 155 | 5 |
| Sep 30, 2024 | 151 | 124 | 459.26% | 146 | 5 |
| Jun 30, 2024 | 28 | -6 | -17.65% | 23 | 5 |
| Mar 31, 2024 | 26 | -5 | -16.13% | 24 | 2 |
| Dec 31, 2023 | 26 | 6 | 30.00% | 24 | 2 |
| Sep 30, 2023 | 27 | 16 | 145.45% | 24 | 3 |
| Jun 30, 2023 | 34 | 23 | 209.09% | 29 | 5 |
| Mar 31, 2023 | 31 | 22 | 244.44% | 27 | 4 |
| Dec 31, 2022 | 20 | 11 | 122.22% | 17 | 3 |
| Jun 30, 2022 | 11 | - | - | 9 | 2 |
| Dec 31, 2021 | 9 | - | - | 9 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| MannKind | 592 |
| MeiraGTx Holdings | 403 |
| Absci | 140 |
| Janux Therapeutics | 109 |
| Theravance Biopharma | 90 |
| CytomX Therapeutics | 69 |
| Alto Neuroscience | 68 |
| Arbutus Biopharma | 19 |
SPRY News
- 21 days ago - neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) - GlobeNewsWire
- 5 weeks ago - ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label - GlobeNewsWire
- 2 months ago - ARS Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 2 months ago - ARS Pharmaceuticals Earnings Call Transcript: Q4 2025 - Transcripts
- 2 months ago - ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization - GlobeNewsWire
- 2 months ago - ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences - GlobeNewsWire
- 3 months ago - ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting - GlobeNewsWire
- 3 months ago - EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to - GlobeNewsWire